3 days popular7 days popular1 month popular3 months popular

New model proposed for clinical trials

Experts across academia, industry and government propose a new method for health care providers to get the right treatments to the right patients at the right time. This new approach, A Proposal for (E2E) , published in Nature Clinical Pharmacology & Therapeutics, recommends a seamless transition from controlled experiments to real-world trials. This continuum will improve the accuracy of treatment selection and better determine how those treatments work on different groups of people.

Efficacy trials are conducted in optimal conditions with patients who have similar characteristics. These trials are typically used to secure regulatory approval for a drug.

Effectiveness trials are conducted in more typical clinical settings, with patients who have varying characteristics. These trials are designed to determine whether treatment effects identified in efficacy trials carry over to more typical uses of drugs in practice.

Currently, efficacy and effectiveness trials are conducted separately, and effectiveness trials may occur years later or not at all. In the E2E model, an effectiveness trial starts immediately after the efficacy trial is completed (or as soon as possible, depending upon a predetermined approval process). Data derived from the efficacy trial can be used to formulate questions to investigate during the effectiveness trial; data derived from the effectiveness trial can then be used to assist patients and providers in making individual treatment decisions.

Development of the E2E approach was led by Harry P. Selker, MD, MSPH of (CTSI) and Tufts Medical Center’s Institute for Clinical Research and Health Policy Studies (ICRHPS), with assistance from Aaron Kirby, MSc, Tufts CTSI’s Manager of Project Administration. The research team includes:

  • Kenneth A. Oye, PhD, Massachusetts Institute of Technology (MIT)
  • Hans-Georg Eichler, MD, MSc,
  • Norman L. Stockbridge, MD, PhD, US Food and Drug Administration, Center for Drug Evaluation and Research
  • Cyrus R. Mehta, PhD, Harvard School of Public Health
  • Kenneth I. Kaitin, PhD, Tufts Center for the Study of Drug Development
  • Newell McElwee, PharmD, MSPH, Merck & Co.
  • Peter K. Honig, MD, MPH, AstraZeneca
  • John K. Erban, MD, Tufts Cancer Center
  • Ralph B. D’Agostino, PhD, Boston University; Harvard Clinical Research Institute

“The E2E approach represents a fundamental shift in a drug development model that has remained basically unchanged for over fifty years,” suggests Kenneth I. Kaitin, PhD, director of the Tufts Center for the Study of Drug Development and research professor at Tufts University School of Medicine. “Although adoption of the approach is not without its challenges, there are likely to be many winners: industry, who will gain better understanding of a drug’s utility, enabling differentiation from competitors; regulators, who will have greater understanding of the drug’s safe and effective use in heterogeneous populations; payers, who will be able to make more informed reimbursement and coverage decisions; and of course physicians and patients, who will benefit from real-world data on the benefits and risks of new medicines.”

“There is growing realization that the difference between efficacy and effectiveness is not just a challenge for drug regulation, but also an underutilised learning opportunity,” says Hans-Georg Eichler, MD, MSc, of European Medicines Agency, “the heterogeneity of real-life treatment populations may help identify non-responders or non-tolerators, and such insights may not be gained from the rather homogenous populations. Realizing this learning opportunity will require pre-planned and cost-effective studies: the E2E trial may be exactly what’s needed.”

The authors hope practitioners will consider the E2E model for future trials.

Source

The E2E investigation and report were supported by the National Institutes of Health National Center for Research Resources (under award number UL1RR025752) and National Center for Advancing Translational Sciences (under award number UL1TR000073). The content is solely the responsibility of the authors and does not necessarily represent the official views of the European Medicines Agency, the US Food and Drug Administration, or the NIH.

Tufts Clinical and Translational Science Institute